Evidence map›Paper›PMID 38759127›Full record

ArticleNeurology2024

Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.

Chen Zhang, Wei Liu, Lijun Wang, Fei Wang, Jiao Li, Zheng Liu, Yinan Zhao, Maigeng Zhou, Peng Yin, Junwei Hao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Geospatial inequalities in severe leprosy disability in Pernambuco before and during COVID-19.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Role of isoflavones in multiple sclerosis.IBRO neuroscience reports · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Rib and Sternum Fractures From Falls: Global Burden of Disease and Predictions.Biomedical engineering and computational biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chen ZhangFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.ORCID 0000-0002-9353-337X
Wei LiuFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.ORCID 0000-0002-1737-8013
Lijun WangFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.
Fei WangFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.
Jiao LiFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.
Zheng LiuFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.
Yinan ZhaoFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.
Maigeng ZhouFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.
Peng YinFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.
Junwei HaoFrom the Department of Neurology (C.Z., F.W., J.L., Z.L., Y.Z., J.H.), Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing; Department of Neurology (C.Z.), PLA Rocket Force Characteristic Medical Center, Beijing; Department of Environmental Health (W.L.), Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou; National Center for Chronic and Non-communicable Disease Control and Prevention (W.L., L.W., M.Z., P.Y.), Chinese Center for Disease Control and Prevention, Beijing; Key Laboratory for Neurodegenerative Diseases of Ministry of Education (J.H.), Beijing; and Beijing Municipal Geriatric Medical Research Center (J.H.), China.ORCID 0000-0002-3075-5434

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMultiple sclerosis (MS) is the leading cause of neurologic disability in young adults, but the burden caused by MS in China is lacking. We aimed to comprehensively describe the prevalence and health loss due to MS by demographic and geographical variables from 1990 to 2019 across China.

methodsData were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019). We used GBD methodology to systematically analyze the prevalence, disability-adjusted life-years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) due to MS by age, sex, and location from 1990 to 2019 in mainland China and its provinces. We also compared the MS burden in China with the world and other Group of 20 (G20) countries.

resultsIn 2019, 42,571 (95% uncertainty interval [UI] 33,001-53,329) individuals in China had MS, which doubled from 1990. The age-standardized prevalence rate of MS was 2.32 per 100,000 (95% UI 1.78-2.91), which increased by 23.31% (95% UI 20.50-25.89) from 1990, with most of the growth occurring after 2010. There was a positive latitudinal gradient with the increasing prevalence from south to north across China. The total DALYs caused by MS were 71,439 (95% UI 58,360-92,254) in 2019, ranking China third among G20 countries. Most of the MS burden in China derived from premature mortality, with the higher fraction of YLLs than that at the global level and most other G20 countries. From 1990 to 2019, the age-standardized DALY and YLL rate had nonsignificant changes; however, the age-standardized YLD rate substantially increased by 23.33% (95% UI 20.50-25.89). The geographic distribution of MS burden varied at the provincial level in China, with a slight downward trend in the age-standardized DALY rates along with increasing Socio-Demographic Index over the study period. DISCUSSION: Although China has a low risk of MS, the substantial and increasing prevalent cases should not be underestimated. The high burden due to premature death and geographic disparity of MS burden reveals insufficient management of MS in China, highlighting the needs for increased awareness and effective intervention.

Indexed as

Global Burden of DiseaseMultiple SclerosisAdolescentAdultAgedChinaCost of IllnessDisability-Adjusted Life YearsFemaleHumansMaleMiddle AgedPrevalenceQuality-Adjusted Life YearsYoung Adult

Identifiers

PMID38759127
PMCPMC11175640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.